tiprankstipranks
Cara Therapeutics (CARA)
NASDAQ:CARA

Cara Therapeutics Stock Analysis & Ratings

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CARA FAQ

What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $7.40 and its highest was $18.93 in the past 12 months.
    What is Cara Therapeutics’s market cap?
    Currently, no data Available
    What is Cara Therapeutics’s price target?
    The average price target for Cara Therapeutics is $28.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $30.00 ,the lowest forecast is $26.00. The average price target represents 143.27% Increase from the current price of $11.51.
      What do analysts say about Cara Therapeutics?
      Cara Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Cara Therapeutics’s upcoming earnings report date?
        Cara Therapeutics’s upcoming earnings report date is Nov 08, 2022 which is in 87 days.
          How were Cara Therapeutics’s earnings last quarter?
          Cara Therapeutics released its earnings results on Aug 08, 2022. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.261 by $0.181.
            Is Cara Therapeutics overvalued?
            According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Cara Therapeutics pay dividends?
              Cara Therapeutics does not currently pay dividends.
              What is Cara Therapeutics’s EPS estimate?
              Cara Therapeutics’s EPS estimate is -$0.39.
                How many shares outstanding does Cara Therapeutics have?
                Cara Therapeutics has 53,591,225 shares outstanding.
                  What happened to Cara Therapeutics’s price movement after its last earnings report?
                  Cara Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.261. Following the earnings report the stock price went up 2.696%.
                    Which hedge fund is a major shareholder of Cara Therapeutics?
                    Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 30M.

                      ---

                      Cara Therapeutics Stock Analysis

                      Smart Score
                      8
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $28.00
                      ▲(143.27% Upside)
                      Moderate Buy
                      The Cara Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cara Therapeutics

                      CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Johnson & Johnson
                      Eli Lilly & Co
                      Pfizer
                      Merck & Company
                      Bristol Myers

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis